Drug Trial Radar · NCT00614523
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Last checked: Nov 20, 2026Latest source record: Nov 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Jul 21, 2008
Primary completion
Mar 31, 2011
Study completion Nov 30, 2015
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Data Monitoring Committee (DMC) for study 20060198 recommended that all subjects discontinue treatment of study drug and continue to be followed for long term follow-up. Amgen adopted the DMC recommendation.
Conditions
- MDS
- Myelodysplastic Syndromes
- Thrombocytopenia
Interventions
PlaceboDrug
Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
RomiplostimBiological
Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Clinically Significant Bleeding EventsTime frame: Test Treatment Period (Weeks 1-26)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.